Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 1
Submit an article Journal homepage
909
Views
34
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Tocilizumab for steroid refractory acute graft-versus-host disease

Julianna V. F. RoddyDepartment of Pharmacy, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USACorrespondence[email protected]
,
Bradley M. HaverkosDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Ali McBrideDepartment of Pharmacy, University of Arizona Cancer Center, Tucson, AZ, USA
,
Kathryn M. LeiningerDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Samantha JaglowskiDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Sam PenzaDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Rebecca KlisovicDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
William BlumDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Sumithira VasuDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Craig C. HofmeisterDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Don M. BensonDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Leslie A. AndritsosDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Steven M. DevineDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
&
Yvonne A. EfeberaDivision of Hematology, Department of Internal Medicine, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
 show all
Pages 81-85 | Received 23 Jan 2015, Accepted 24 Apr 2015, Published online: 03 Jul 2015

References

  • Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009;114:4327–4336.
  • Berger M, Biasin E, Saglio F, et al. Innovative approaches to treat steroid-resistant or steroid refractory GVHD. Bone Marrow Transplant 2008;42(Suppl. 2):S101–105.
  • Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet 2009;373(9674):1550–1561.
  • Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109: 4119–4126.
  • Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82: 45–52.
  • Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004;89:1352–1359.
  • Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005;35:1003–1010.
  • Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:56–61.
  • Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005;23:2661–2668.
  • Cavet J, Dickinson AM, Norden J, et al. Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001;98:1594–1600.
  • Pihusch M, Pihusch R, Fraunberger P, et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 2006; 76:93–101.
  • Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009;114:891–900.
  • Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011;17:77–88.
  • Givon T, Revel M, Slavin S. Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. Blood 1994;83:1690–1697.
  • Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761–1769.
  • Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007;46:771–774.
  • Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371(9617):998–1006.
  • Gergis U, Arnason J, Yantiss R, et al. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Oncol 2008;28(30):e602–4.
  • Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1862–1868.
  • Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–828.
  • Kennedy GA, Varelias A, Vuckovic S, et al. The addition of interleukin-6 inhibition to standard GVHD prophylaxis prevents acute GVHD: interim results of a phase I/II clinical study. Blood 2013;122:908.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.